Female Sexual Dysfunction: A Clinical Guide for Providers

Written by Empire Medical Training Editorial Team

Medically reviewed by Betsy Greenleaf, DO Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging

Updated June 2026 ·11 min read

Female sexual dysfunction is one of the most prevalent yet least addressed concerns in clinical practice. As Empire's Director of Anti-Aging, board-certified OB/GYN and urogynecologist Dr. Betsy Greenleaf frames it, sexual health is a vital part of overall well-being that is routinely overlooked in the exam room — and when clinicians improve their own knowledge and comfort discussing it, they break down barriers, reduce stigma, and deliver more complete care. This guide is the hub for that conversation: what female sexual dysfunction is, how it is classified, what drives it, and how it is evaluated and treated.

This is part of Empire's broader sexual health resource center and is written as clinical education for providers. It is not medical advice, and nothing here is a treatment protocol or a substitute for individualized clinical judgment and current standards of care.

What is female sexual dysfunction?

Female sexual dysfunction is a broad umbrella term encompassing any issue that prevents a woman from experiencing satisfaction during sexual activity. The classification clinicians use maps to the phases of the sexual response cycle, and Dr. Greenleaf teaches four practical categories:

• Desire disorders — persistently low or absent interest in sexual activity, the most common being hypoactive sexual desire disorder (HSDD).
• Arousal disorders — difficulty attaining or maintaining the physical arousal response, including lubrication and genital engorgement.
• Orgasmic disorders — persistent delay in, or absence of, orgasm despite adequate stimulation and arousal.
• Sexual pain disorders — pain associated with intercourse or genital contact, including dyspareunia, vaginismus, and the genitourinary syndrome of menopause.

A point Dr. Greenleaf emphasizes is that the older, linear Masters and Johnson model — desire leading to arousal, plateau, orgasm, and resolution — does not capture most women's experience well. The Basson model is a better representation: arousal can precede desire rather than follow it. Many women, especially in long-term relationships and with age, do not feel spontaneous desire; instead, being receptive to intimacy allows psychological arousal and pelvic blood flow to build, and desire follows. She finds that explaining this model to patients reduces anxiety around sex, because it reframes "I don't feel desire first" as normal physiology rather than dysfunction.

How common — and how underdiagnosed

Female sexual dysfunction is common and substantially underreported. Studies estimate that roughly 43% of women experience some form of sexual dysfunction, and prevalence climbs with age and menopausal status. As Dr. Greenleaf notes, these figures are considered grossly underreported because of the embarrassment and taboo that still surround the subject — both for patients and for clinicians who never ask.

The category-specific numbers reinforce how routine these concerns are. Low libido is reported in roughly 27% to 52% of menopausal women, with the highest rates after surgical menopause. Genitourinary and dryness symptoms are reported by a large majority of postmenopausal women — in some cohorts, the overwhelming majority describe vaginal dryness, reduced lubrication, or painful intercourse. The practical takeaway is that if a clinician is not screening for sexual concerns, the silence in the chart reflects unasked questions, not absence of the problem.

Desire disorders and HSDD

The most common desire disorder is hypoactive sexual desire disorder (HSDD) — persistent or recurrent low interest in sexual activity, few or no sexual thoughts or fantasies, and reluctance to initiate, severe enough to cause personal distress or relationship difficulty. The distress criterion matters: low desire alone is not a disorder unless it troubles the patient or strains the relationship.

Dr. Greenleaf is direct about the central truth here: there is no "horny pill," because the brain is the most important sexual organ. Without mental stimulation and a relaxed state, no medication that simply increases blood flow will produce desire. She also draws on the neurobiology of relationships — novelty produces the dopamine surges of early relationships, and habituation naturally cools spontaneous passion over time — to help patients understand that waning desire in long-term couples is physiology, not failure, and is often best addressed by reintroducing novelty alongside any medical therapy.

For a deeper look at the workup and treatment of desire disorders, see the dedicated guide to low libido in women.

Arousal and orgasm disorders

Arousal disorders involve a persistent inability to attain or sustain the physical arousal response — adequate lubrication and genital engorgement — despite the desire to. Orgasmic disorders involve a recurrent delay in, or absence of, orgasm after sufficient stimulation. The two frequently coexist and overlap with desire concerns, which is why classification is a starting point rather than a rigid box.

Physiologically, arousal depends on nitric oxide–mediated vasodilation increasing blood flow to the clitoris, labia, and vaginal walls, with parasympathetic ("rest and digest") tone permitting that response. This is why Dr. Greenleaf stresses that stress is the biggest killer of libido and arousal: when the sympathetic "fight or flight" system is active, blood flow is shunted away from the pelvis, and sex and stress simply cannot coexist. Evaluating and treating arousal and orgasm concerns therefore means looking well beyond the genitals. The companion guide to female arousal and orgasm disorders covers these conditions in detail.

Pain disorders and GSM

Sexual pain is a broad category that any clinician offering this service must take seriously. It includes dyspareunia (painful intercourse), vaginismus (involuntary pelvic floor spasm that can make penetration painful or impossible), vulvodynia, and pudendal neuralgia. Dr. Greenleaf is emphatic that pain that persists beyond about three months risks central upregulation of pain neurons, which makes it harder to treat — so sexual pain should be assessed and managed like any chronic pain condition, often with a multidisciplinary team.

The most common driver of pain and dryness in midlife is the genitourinary syndrome of menopause (GSM), formerly called atrophic vaginitis. Falling estrogen — after menopause, or transiently with breastfeeding, certain cancer treatments, or anti-estrogen medications — thins and inflames the vaginal walls and produces dryness, irritation, urinary symptoms, and painful intercourse. The renamed term reflects that this is a combined vaginal and urinary syndrome, not an isolated dryness complaint. GSM is also one of the most treatable causes of female sexual dysfunction, which is why it deserves its own focused guide: vaginal dryness and GSM.

The causes: a biopsychosocial picture

Dr. Greenleaf's clinical philosophy is to look at the roots under the leaves of the tree — sexual dysfunction is usually the symptom of a larger problem, not the problem itself. The contributing factors span several overlapping domains:

• Hormonal and menopausal — declining estrogen drives GSM and dryness; testosterone and thyroid status influence desire and energy. Hormones, she reminds clinicians, are a tool, not the whole answer.
• Vascular — arousal is a blood-flow event, so the same vascular processes that affect cardiovascular health affect genital engorgement and lubrication.
• Neurological — the limbic system, hypothalamus, and pelvic nerves coordinate the response; nerve injury or central sensitization can disrupt it.
• Psychological and relational — how a woman feels about herself, her partner, and her relationship strongly shapes desire and response; stress, anxiety, depression, past trauma, and relationship conflict are central, not peripheral.
• Medications and lifestyle — antidepressants, hormonal contraceptives, and other agents can blunt desire and arousal; sleep, diet, exercise, and chronic stressors all matter.

The unifying thread is the nervous system. Because chronic stress keeps the body in a sympathetic state that suppresses libido and fertility, Dr. Greenleaf teaches that even excellent hormone therapy will underperform if stress and the brain–body connection are ignored.

Evaluation: the sensitive history

Evaluation begins not with a test but with rapport. The first step is establishing a trusting, non-judgmental environment and assuring confidentiality and privacy, so the patient feels safe raising concerns she may never have voiced to a clinician before. From there, a detailed sexual history explores the specific nature of the dysfunction — desire, arousal, orgasm, or pain — along with onset, duration, frequency, aggravating and relieving factors, and past and current relationships and experiences.

A thorough workup is deliberately biopsychosocial and whole-body. It includes a general medical and psychosocial history, a focused physical and pelvic examination to identify dryness, atrophy, or pain, and consideration of sources outside the pelvis — diabetes, cardiovascular disease, thyroid dysfunction, neurological contributors, and lifestyle stressors. Validated instruments such as the Female Sexual Function Index (FSFI), which assesses desire, arousal, lubrication, orgasm, satisfaction, and pain, help quantify the problem and track response to treatment. Targeted labs — hormone levels, glucose, thyroid, and relevant markers — are ordered based on the clinical picture. The specific examination technique, questionnaire scoring, and decision-making are taught hands-on in Empire's course.

The treatment landscape

Because the causes are multifactorial, treatment is individualized and often combined. The major categories, each weighted to the underlying driver, include:

• Hormonal therapy — local vaginal estrogen, DHEA, or testosterone are highly effective for GSM-related dryness and dyspareunia, with low systemic exposure; systemic hormones address broader menopausal and desire concerns. See hormones and sexual function and Empire's hormone replacement therapy resources.
• Regenerative injections (PRP / the O-Shot) — platelet-rich plasma injected into the anterior vaginal wall and clitoral area aims to improve sensitivity, lubrication, and arousal. Dr. Greenleaf teaches this candidly: the evidence is still emerging, the "O-Shot" name is trademarked, and results derive from growth-factor–driven remodeling over roughly four to six weeks. See PRP for sexual health.
• FDA-approved medications for HSDD — flibanserin (a daily central-acting agent) and bremelanotide (an on-demand subcutaneous injection) are approved for HSDD in premenopausal women; both show modest effect sizes and specific safety counseling.
• Peptides — PT-141 (bremelanotide's peptide) is a melanocortin receptor agonist that acts centrally on desire and arousal; kisspeptin and oxytocin are also discussed. See the peptide guide to PT-141.
• Lubricants and vaginal moisturizers — first-line for dryness and friction; Dr. Greenleaf stresses matching vaginal pH (3.5–4.5) and using lower-osmolality products to protect the microbiome.
• Therapy and pelvic floor care — psychosexual counseling, CBT, mindfulness, and pelvic floor physical therapy address the relational, psychological, and musculoskeletal contributors that no injection can fix.

Throughout, the honest framing matters: hormones and lubricants have strong support; several regenerative and device-based options (PRP, energy-based vaginal treatments) remain emerging, with limited long-term data and, in some cases, FDA caution about marketing claims. A competent provider knows which is which.

Training to offer female sexual medicine

Offering this service well requires more than a procedure checklist. It calls for the comfort to take a sensitive history, the framework to classify dysfunction correctly, the judgment to work up the biopsychosocial roots, and the evidence base to deploy hormones, peptides, regenerative injections, devices, and referrals appropriately. Dr. Greenleaf also frames the practice opportunity honestly: the sexual wellness market is large and growing, much of this care is delivered cash-pay, and a membership or cash-based model allows the longer, more thorough appointments these patients need.

Empire Medical Training teaches female sexual medicine in depth — alongside male sexual health — within its provider-focused sexual health and regenerative curriculum, including hands-on instruction in the procedural components.